Chronic Atrophic Gastritis

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

TM
Trio MedicinesUK - London
2 programs
2
YF476Phase 21 trial
YF476Phase 21 trial
Active Trials
NCT01444014TerminatedEst. May 2012
NCT01339169CompletedEst. Dec 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Trio MedicinesYF476
Trio MedicinesYF476

Clinical Trials (2)

NCT01444014Trio MedicinesYF476

YF476 and Type I Gastric Carcinoids (Norway)

Start: Jun 2011Est. completion: May 2012
Phase 2Terminated
NCT01339169Trio MedicinesYF476

YF476 and Type I Gastric Carcinoids

Start: Jan 2011Est. completion: Dec 2013
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space